Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma

Dermatology : International Journal for Clinical and Investigative Dermatology
M T FierroM G Bernengo

Abstract

Response of cutaneous T-cell lymphoma (CTCL) to systemic chemotherapy is unsatisfactory: despite an initially high response rate (RR), duration is always short-lived. To investigate the capability of a third-generation regimen including idarubicin in improving RR and response duration in CTCL patients. Twenty-five patients with advanced CTCL (stages IIB and IV) were treated with a 12-week polychemotherapeutic regimen (VICOP-B), which foresees the use of idarubicin in association with etoposide, cyclophosphamide, vincristine, prednisone and bleomycin. The overall objective RR was 80% (36% complete response). The mycosis fungoides (MF) RR was 84%, with a median duration of 8.7 months. The pleomorphic-lymphoma RR was higher (100%), but the corresponding response duration was shorter (median: 3 months). No responses were documented in Sézary syndrome. VICOP-B regimen is effective and feasible as first-line chemotherapy in advanced MF, with or without extracutaneous involvement.

Citations

Apr 30, 2002·American Journal of Clinical Dermatology·Narin ApisarnthanaraxMadeleine Duvic
Jun 30, 2004·Leukemia & Lymphoma·D A PichardoS T Rosen
Dec 17, 2014·Expert Review of Hematology·Bláithín Moriarty, Sean Whittaker
Apr 1, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Franz TrautingerSean Whittaker
Oct 5, 2015·Dermatologic Clinics·Catherine G Chung, Brian Poligone
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Luigi ZinzaniMichele Baccarani
Oct 18, 2005·The British Journal of Dermatology·T YokoteT Hanafusa
Nov 28, 2020·The Journal of Dermatology·Mikio OhtsukaMakoto Sugaya

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.